View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2012	Oct. 31, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		58,831,878
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 17,628,000	$ 36,922,000
Accounts receivable, net of reserves of $455,000 and of $474,000 in 2012 and 2011, respectively	1,463,000	2,260,000
Inventories, net	3,411,000	3,318,000
Other current assets	1,090,000	837,000
Total current assets	23,592,000	43,337,000
Property and equipment, net	2,242,000	1,711,000
Restricted cash and cash equivalents	350,000	350,000
Investment in joint venture	122,000	250,000
Other assets	1,756,000	1,772,000
Intangibles, net	26,000	192,000
Goodwill	3,922,000	3,922,000
Total assets	32,010,000	51,534,000
Current liabilities:
Accounts payable and accrued expenses	5,588,000	5,334,000
Current portion of long-term obligations	9,767,000	2,487,000
Total current liabilities	15,355,000	7,821,000
Deferred revenues, related party	1,107,000	3,520,000
Deferred revenues	5,147,000	5,244,000
Warrant liability	1,871,000	627,000
Option Liability	2,400,000	1,910,000
Long-term deferred rent	684,000	504,000
Long-term obligations, net of discount, less current portion	15,178,000	21,962,000
Total liabilities	41,742,000	41,588,000
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011	0	0
Common stock, $0.001 par value; 95,000,000 shares authorized; 58,720,627 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively	59,000	57,000
Additional paid-in capital	261,113,000	252,338,000
Accumulated deficit	(270,904,000)	(242,449,000)
Total stockholders' equity (deficit)	(9,732,000)	9,946,000
Total liabilities and stockholders' equity (deficit)	$ 32,010,000	$ 51,534,000

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Accounts receivable, reserves	$ 455,000	$ 474,000
Stockholders' equity (deficit):
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	95,000,000	95,000,000
Common stock, shares issued (in shares)	58,720,627	58,720,627
Common stock, shares outstanding (in shares)	56,594,683	56,594,683

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) [Abstract]
Product revenues	$ 1,314,000	$ 2,134,000	$ 4,741,000	$ 5,908,000
Cost of product revenues	703,000	942,000	2,588,000	2,893,000
Gross profit	611,000	1,192,000	2,153,000	3,015,000
Development revenues:
Development, related party	0	0	2,413,000	1,231,000
Research grant and other	2,000	5,000	21,000	19,000
Total development revenues	2,000	5,000	2,434,000	1,250,000
Operating expenses:
Research and development	3,555,000	2,830,000	9,615,000	8,948,000
Sales and marketing	2,450,000	3,618,000	7,406,000	10,560,000
General and administrative	3,777,000	3,538,000	11,489,000	11,230,000
Change in fair value of warrant liability	863,000	(1,536,000)	1,244,000	(3,714,000)
Change in fair value of option liability	300,000	570,000	490,000	680,000
Total operating expenses	10,945,000	9,020,000	30,244,000	27,704,000
Operating loss	(10,332,000)	(7,823,000)	(25,657,000)	(23,439,000)
Other income (expense):
Interest income	0	3,000	3,000	7,000
Interest expense	(857,000)	(489,000)	(2,582,000)	(1,923,000)
Other income (expense), net	(17,000)	25,000	(91,000)	(36,000)
Equity loss from investment in joint venture	(42,000)	(51,000)	(128,000)	(153,000)
Total other income (expense)	(916,000)	(512,000)	(2,798,000)	(2,105,000)
Net loss	$ (11,248,000)	$ (8,335,000)	$ (28,455,000)	$ (25,544,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.19)	$ (0.15)	$ (0.49)	$ (0.48)
Basic and diluted weighted average common shares (in shares)	58,713,036	53,900,250	58,292,911	52,775,861

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (28,455,000)	$ (25,544,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	712,000	621,000
Amortization of deferred financing costs and debt discount	706,000	471,000
Provision for doubtful accounts	99,000	274,000
Change in fair value of warrant liability	1,244,000	(3,714,000)
Change in fair value of option liability	490,000	680,000
Share-based compensation expense	2,907,000	2,578,000
Equity loss from investment in joint venture	128,000	153,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	698,000	(168,000)
Inventories	(93,000)	(775,000)
Other current assets	(253,000)	132,000
Other assets	16,000	(764,000)
Accounts payable and accrued expenses	254,000	(396,000)
Deferred revenues, related party	(2,413,000)	(1,231,000)
Deferred revenues	(97,000)	189,000
Long-term deferred rent	180,000	70,000
Net cash used in operating activities	(23,877,000)	(27,424,000)
Cash flows from investing activities:
Purchases of property and equipment	(1,077,000)	(458,000)
Net cash used in investing activities	(1,077,000)	(458,000)
Cash flows from financing activities:
Principal payments on long-term debt	(210,000)	(4,460,000)
Proceeds from long-term debt	0	9,444,000
Debt issuance costs and loan fees	0	(719,000)
Proceeds from exercise of employee stock options and warrants	988,000	2,849,000
Proceeds from sale of common stock	4,946,000	9,038,000
Costs from sale of common stock	(64,000)	(135,000)
Net cash provided by financing activities	5,660,000	16,017,000
Net decrease in cash and cash equivalents	(19,294,000)	(11,865,000)
Cash and cash equivalents at beginning of period	36,922,000	52,668,000
Cash and cash equivalents at end of period	17,628,000	40,803,000
Cash paid during period for:
Interest	1,906,000	1,458,000
Final payment fee on long-term debt	0	419,000
Supplemental schedule of non-cash operating, investing and financing activities:
Fair Value Of Warrants Allocated To additional paid in capital	0	267,000
Capital equipment lease	$ 0	$ 85,000

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2012
Basis of Presentation [Abstract]
Basis of Presentation	1. Basis of Presentation Our accompanying unaudited consolidated condensed financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at September 30, 2012 has been derived from the audited financial statements at December 31, 2011, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2011.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Use of Estimates	9 Months Ended
Use of Estimates	Sep. 30, 2012
Use of Estimates [Abstract]
Use of Estimates	2. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, evaluating goodwill for impairment, valuing our put option arrangement with Olympus Corporation, valuing warrants, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories. Actual results could differ from these estimates. Current economic conditions, including illiquid credit markets and volatile equity markets, contribute to the inherent uncertainty of such estimates. Management's estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.

Capital Availability	9 Months Ended
Capital Availability	Sep. 30, 2012
Capital Availability [Abstract]
Capital Availability	3. Capital Availability We incurred net losses of $11,248,000 and $28,455,000 for the three and nine months ended September 30, 2012 and $8,335,000 and $25,544,000 for the three and nine months ended September 30, 2011, respectively. We have an accumulated deficit of $270,904,000 as of September 30, 2012. Additionally, we have used net cash of $23,877,000 and $27,424,000 to fund our operating activities for the nine months ended September 30, 2012 and 2011, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital. We believe we have enough cash to fund operations into the first quarter of 2013, which factors in the minimum cash and cash liquidity requirements of the Amended and Restated Loan and Security Agreement with the Lenders, which requires that we maintain at least three months of cash on hand to avoid an event of default under the Loan and Security Agreement. In order to continue operations through the next twelve months, we are pursuing additional cash through strategic corporate partnerships and future sales of equity in addition to our gross profits. We have an established history of raising capital through these platforms, and we are currently involved in negotiations with multiple parties. In the continued absence of positive cash flows from operations, no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if available, on terms acceptable to us in the future. During 2012, we expanded our commercialization activities while simultaneously pursuing available financing sources to support operations and growth. We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future operations. If we cannot do so when required, we would need to reduce our research, development, and administrative operations, including reductions of our employee base, in order to offset lack of available funding. We continue to evaluate market conditions and available financing opportunities as part of our normal course of business.

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2012
Recently Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In May 2011, the FASB revised the fair value measurement and disclosure requirements to align the requirements under GAAP and International Financial Reporting Standards ("IFRS"). The guidance clarifies the FASB's intent about the application of existing fair value measurements and requires enhanced disclosures, most significantly related to unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance is effective prospectively during interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on our consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=6958853&loc=d3e46468-122699

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22580-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

Warrant Liability

9 Months Ended

Sep. 30, 2012

Warrant Liability [Abstract]

Warrant Liability

5. Warrant Liability

Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in fair value included in net earnings (loss). The fair value of the liability associated with the warrants with this reset feature increased to $1,871,000 as of September 30, 2012, which resulted in a $863,000 and $1,244,000 loss from the change in fair value of warrants for the three and nine months ended September 30, 2012, respectively.

All future changes in the fair value of the warrants will be recognized currently in earnings until such time as the warrants are exercised or expire. These warrants are not traded in an active securities market, and as such, we estimated the fair value of these warrants using an option pricing model with the following assumptions:

	As of September 30, 2012			As of December 31, 2011
Expected term	0.87 years			1.61 years
Common stock market price	$	4.41		$	2.20
Risk-free interest rate		0.17	%		0.19	%
Expected volatility		74.94	%		69.98	%
Resulting fair value (per warrant)	$	0.93		$	0.32

Expected volatility is based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the interest rate for treasury constant maturity instruments published by the Federal Reserve Board that is closest to the expected term of the warrants. The fair value of these warrants also incorporates our assumptions about future equity issuances and their impact to the down-round protection feature.

Fluctuations in the fair value of the warrants are impacted by unobservable inputs, most significantly the assumption with regards to future equity issuances and their impact to the down-round protection feature. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value measurement.

Long-term Debt	9 Months Ended
Long-term Debt	Sep. 30, 2012
Long-term Debt [Abstract]
Long-term Debt	6. Long-term Debt On September 9, 2011 we entered into a Second Amendment to the Amended and Restated Loan and Security Agreement (loan agreement) with General Electric Capital Corporation (GECC), Silicon Valley Bank (SVB) and Oxford Finance Corporation (together, the "Lenders"), pursuant to which the Lenders increased the prior term loan made to the Company to a principal amount of $25.0 million (Term Loan), subject to the terms and conditions set forth in the loan agreement. The Term Loan accrues interest at a fixed rate of 9.87% per annum. Pursuant to the loan agreement, we are required to make (i) twelve (12) equal consecutive monthly principal payments of $20,833 on the first day of each calendar month, commencing on October 1, 2011, (ii) twenty-nine (29) equal consecutive monthly principal payments of $825,000 on the first day of each calendar month, commencing on October 1, 2012, and (iii) and one (1) final principal payment of $825,000 on March 1, 2015. In addition, the maturity date of the Term Loan has been extended until March 1, 2015, and at maturity of the Term Loan, the Company will make a final payment fee equal to 5% ($1,250,000) of the Term Loan. We may incur additional fees if we elect to prepay the Term Loan. In connection with the Term Loan, on September 9, 2011, we issued to the Lenders warrants to purchase up to an aggregate of 132,891 shares of our common stock at an exercise price of $3.01 per share. These warrants are immediately exercisable and will expire on September 9, 2018. The Term Loan amended the Amended and Restated Loan and Security Agreement, of which an aggregate balance of approximately $15.6 million remained outstanding along with a prorated final payment fee of $419,000. The net proceeds of the Term Loan, after payment of lender fees and expenses, were approximately $8.6 million. We accounted for this amendment as debt modification since the terms of the amended Term Loan and the Original Term Loan were not substantially different and as present value of cash flows of the modified instrument (using a net method of comparing the present value of cash flows related to the lowest common principal balance between the old and the new loans) was within 10% of the original debt instrument. Accordingly, the fees associated with the amended Term Loan of $300,000, final payment fee of $1,250,000, and the existing unamortized debt discount from the Original Term Loan of $332,000 will be amortized as an adjustment of interest expense over the term of the Amended Term Loan using the effective interest method. We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values. The fair value of the warrants issued to the Lenders is calculated utilizing the Black-Scholes option-pricing model. We are amortizing the relative fair value of the warrants as a discount of $267,000 over the term of the loan using the effective interest method, with an effective interest rate of 13.63%. If the maturity of the debt is accelerated due to an event of default, then the amortization would be accelerated. The Term Loan is collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets; provided however, that if the Company does not maintain certain cash ratios, the security interest automatically will be deemed to include the Company's intellectual property assets. As of September 30, 2012, we were in compliance with our financial and non-financial covenants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Revenue Recognition

9 Months Ended

Sep. 30, 2012

Revenue Recognition [Abstract]

Revenue Recognition

7. Revenue Recognition

Product Sales

We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.

For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. Revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer's obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products.

For sales that include multiple deliverables, such as sales of our StemSource® Cell Bank (cell bank), we account for products or services (deliverables) separately rather than as a combined unit. Stem cell banks typically consist of a complex array of equipment, proprietary knowledge, license rights, and services, including one or more StemSource® devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting services, installation and training services concurrent with the installation of the cell bank. Web hosting, technical support and maintenance services are generally provided for a period of up to one year subsequent to the date of sale. FASB authoritative guidance requires an evaluation of these deliverables to determine the appropriate "units of accounting" for purposes of revenue recognition. Based on this evaluation, we have identified the following units of accounting:

initial consulting services;

license rights and standard operating procedures;

equipment and supplies, installation and training;

database hosting services;

technical support services; and

maintenance services.

FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence ("VSOE"); (b) third-party evidence ("TPE"); or (c) management estimates. This guidance requires arrangement consideration to be allocated at the inception of the arrangement to all deliverables using the relative selling price method. For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available. In the absence of VSOE, we use competitors' products or services considered largely interchangeable with our own or management's best estimate. Revenue allocated to each unit of accounting is calculated and recognized based on the relative selling price of each deliverable. Future services such as web hosting and ongoing maintenance are deferred and recognized into income as the services are provided, generally over one year following the installation of the equipment.

Concentration of Significant Customers

One direct customer comprised 16% of our revenue recognized for the nine months ended September 30, 2012. Our Asia-Pacific and North America region sales accounted for 67% of our revenue recognized for the nine months ended September 30, 2012. Additionally, three direct customers accounted for 44% of total outstanding accounts receivable as of September 30, 2012.

For the nine months ended September 30, 2011, our sales were concentrated in one direct customer and one distributor, which in aggregate comprised 31% of our revenue recognized for the nine months ended September 30, 2011. Our Asia-Pacific and North America region sales accounted for 68% of our revenue recognized for the nine months ended September 30, 2011. Additionally, one distributor and one direct customer accounted for 28% of total outstanding accounts receivable as of September 30, 2011.

Research and Development

We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the National Institutes of Health ("NIH"). Revenue earned under development agreements is classified as either research grant or development revenues depending on the nature of the arrangement. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with grants are recorded as research grant and other within development revenues. Research grant revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. Additionally, research and development arrangements we have with commercial enterprises such as Olympus and Senko are considered a key component of our central and ongoing operations. Accordingly, when recognized, the inflows from such arrangements are presented as revenues in our statements of operations.

In the third quarter of 2012, we were awarded a contract to develop a new countermeasure for thermal burns valued at up to $106 million with the U.S. Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA). The initial base period includes $4.7 million over two years and covers preclinical research and continued development of Cytori's Celution® system to improve cell processing. The additional contract options, if fully executed, cover clinical development through FDA approval under a device-based PMA regulatory pathway. This is a cost reimbursement contract and we expect the accounting treatment for the initial base period to be similar to NIH grants as discussed above. We expect reimbursement and associated revenues for this contract to begin in the fourth quarter of 2012.

We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006. We recorded upfront fees totaling $28,311,000 as deferred revenues, related party. In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution® System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution® System platform. The license and development services are not separable and as a result the recognition of this deferred amount requires achievement of service related milestones, under a proportional performance methodology. If and as such revenues are recognized, deferred revenue will be decreased. Proportional performance methodology was elected due to the nature of our development obligations and efforts in support of the Joint Venture ("JV"), including product development activities and regulatory efforts to support the commercialization of the JV products. The application of this methodology uses the achievement of R&D milestones as outputs of value to the JV. We received up-front, non-refundable payments in connection with these development obligations, which we have broken down into specific R&D milestones that are definable and substantive in nature, and which will result in value to the JV when achieved. As our research and development efforts progress, we periodically evaluate, and modify if necessary, the milestone points in our proportional performance model to ensure that revenue recognition accurately reflects our best estimate of substantive value deliverable to the JV. Revenue will be recognized as the above mentioned R&D milestones are completed. During the three and nine months ended September 30, 2011, we recognized development revenues of $0 and $1,231,000 of revenue associated with our arrangement with Olympus as a result of achieving a product development milestone related to additional preproduction development of the Celution® One System. During the three and nine months ended September 30, 2012, we recognized $0 and $2,413,000 of revenue associated with our arrangement with Olympus as a result of two remaining milestones for the APOLLO and PRECISE clinical trials that were reached upon the completion of all patient follow up prodedures. All related development costs are expensed as incurred and are included in research and development expense on our statements of operations. To date under the contract, of the $28,311,000 originally deferred, we have recognized a total of $27,204,000 through September 30, 2012.

Under a Distribution Agreement with Senko, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan. We have also earned or will be entitled to earn additional payments under the Distribution Agreement based on achieving certain defined and substantive research and development milestones. There was no development revenue recognized related to this agreement during the three and nine months ended September 30, 2012 and 2011, respectively.

Inventories

9 Months Ended

Sep. 30, 2012

Inventories [Abstract]

Inventories

8. Inventories

Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.

Inventories consisted of the following:

	September 30,		December 31,
	2012		2011

Raw materials	$	1,500,000	$	1,503,000
Work in process		328,000		790,000
Finished goods		1,583,000		1,025,000
	$	3,411,000	$	3,318,000

Share-Based Compensation

9 Months Ended

Sep. 30, 2012

Share-Based Compensation [Abstract]

Share-Based Compensation

9. Share-Based Compensation

Stock Options

During the first quarter of 2012, we issued to our directors and executive officers options to purchase an aggregate of 690,000 shares of our common stock, with four-year vesting for our officers and two-year vesting for our directors. The grant date fair value of the awards granted to our officers was $2.10 per share and to our directors was $1.35 per share. The resulting share-based compensation expense of $1,373,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.

During the first quarter of 2011, we issued to our directors, executive officers and certain non-executive employees options to purchase an aggregate of 692,500 shares of our common stock, with four-year vesting for our officers and employees and two-year vesting for our directors. The grant date fair value of the awards granted to our officers and employees was $3.46 and to our directors was $3.15 per share. The resulting share-based compensation expense of $2,375,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.

Restricted Stock Awards

During the first quarter of 2012, we issued to our executive officers 190,000 shares of restricted stock. The stock award is scheduled to fully vest on January 10, 2013, subject to the officer's continued employment with the Company through the vesting date. The resulting share-based compensation expense of $654,000 will be recognized as expense over the respective vesting periods.

Performance-Based Restricted Stock Awards

We granted 246,225 performance-based restricted stock awards under the 2004 Equity Incentive Plan in February 2011. The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012. No compensation expense was recognized related to these awards.

In January 2012, we granted 276,375 performance-based restricted stock awards under the 2004 Equity Incentive Plan. The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company's products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%). To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012. Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards. We recognized $29,000 and $78,000 of compensation expense related to these awards, respectively, during the three and nine months ended September 30, 2012.

The following table summarizes activity with respect to the performance based restricted stock awards during the nine months ended September 30, 2012:

	Restricted Stock Awards			Weighted Average Grant- Date Fair Value
Outstanding at January 1, 2012		246,225		$	5.82
Granted		276,375		$	3.44
Vested		0
Cancelled/forfeited		(261,300	)	$	5.68
Outstanding at September 30, 2012		261,300		$	3.44
Vested at September 30, 2012		0

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Loss per Share	9 Months Ended
Loss per Share	Sep. 30, 2012
Loss per Share [Abstract]
Loss per Share	10. Loss per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants, restricted stock and performance based restricted stock awards for all periods presented. We have excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the three and nine months ended September 30, 2012 and 2011, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 18,193,938 for the three and nine month periods ended September 30, 2012 and 19,503,013 for the three and nine month periods ended September 30, 2011, respectively.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2012
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements was estimated based on current schedules of pre-clinical and clinical studies in progress. As of September 30, 2012, we have pre-clinical research study obligations of $23,000 (which are expected to be fully completed within a year) and clinical research study obligations of $11,600,000 ($3,700,000 of which are expected to be completed within a year). Should the timing or the budgets of the pre-clinical and clinical trials change, the timing and amounts of the payments for these obligations would also change. During 2008, we entered into a supply agreement with a minimum purchase requirements clause. As of September 30, 2012, we have minimum purchase obligations of $2,191,000 ($1,341,000 of which are expected to be paid within a year). We have entered into several lease agreements for our headquarters office location as well as international office locations and corporate housing for our employees on international assignments. As of September 30, 2012, we have remaining lease obligations of $9,486,000 ($1,986,000 of which are expected to be completed within a year). We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. When evaluating contingencies, we may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against us may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of our potential liability. We regularly review contingencies to determine the adequacy of our accruals and related disclosures. The amount of ultimate loss may differ from these estimates, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding could reasonably have a material effect on our business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact any such losses, damages or remedies may have on our consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole. Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations. Refer to note 12 for a discussion of our commitments and contingencies related to our transactions with Olympus, including (a) our obligation to the Joint Venture in future periods and (b) certain put and call rights embedded in the arrangements with Olympus.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Transactions with Olympus Corporation

9 Months Ended

Sep. 30, 2012

Transactions with Olympus Corporation [Abstract]

Transactions with Olympus Corporation

12. Transactions with Olympus Corporation

Initial Investment by Olympus Corporation in Cytori

In 2005, we entered into a common stock purchase agreement with Olympus in which we received $11,000,000 in cash proceeds. We received an additional $11,000,000 from Olympus in August 2006 for the issuance of approximately 1,900,000 shares of our common stock at $5.75 per share. We received an additional $6,000,000 from Olympus in August 2008 for the issuance of 1,000,000 unregistered shares of our common stock at $6.00 per share and 500,000 common stock warrants (with an original exercise price of $8.50 per share) under a private placement offering.

As of September 30, 2012, Olympus holds approximately 6.8% of our issued and outstanding shares. Additionally, Olympus has a right, which it has not yet exercised, to designate a director to serve on our Board of Directors.

Formation of the Olympus-Cytori Joint Venture

In 2005, we entered into a joint venture and other related agreements (the "Joint Venture Agreements") with Olympus. The Joint Venture is owned equally by Olympus and us. We have determined that the Joint Venture is a variable interest entity or VIE, but that Cytori is not the VIE's primary beneficiary. Accordingly, we have accounted for our interests in the Joint Venture using the equity method of accounting, since we can exert significant influence over the Joint Venture's operations. At September 30, 2012, the carrying value of our investment in the Joint Venture is $122,000. We are under no obligation to provide additional funding to the Joint Venture, but may choose to do so. We made no cash contributions to the Joint Venture during the three and nine months ended September 30, 2012 and 2011.

Put/Calls and Guarantees

The Shareholders' Agreement between Cytori and Olympus provides that in certain specified circumstances of our insolvency or if we experience a change in control, Olympus will have the rights to (i) repurchase our interests in the Joint Venture at the fair value of such interests or (ii) sell its own interests in the Joint Venture to Cytori (the "Put") at the higher of (a) $22,000,000 or (b) the Put's fair value.

At September 30, 2012 and December 31, 2011, the estimated fair value of the Put was $2,400,000 and $1,910,000, respectively. Fluctuations in the Put value are recorded in the consolidated condensed statements of operations as a component of change in fair value of option liabilities. The estimated fair value of the Put has been recorded as a long-term liability in the caption option liability in our consolidated condensed balance sheets.

The valuations of the Put were completed using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation). The valuations are based on assumptions as of the valuation date with regard to the market value of Cytori and the estimated fair value of the Joint Venture, the expected correlation between the values of Cytori and the Joint Venture, the expected volatility of Cytori and the Joint Venture, the bankruptcy recovery rate for Cytori, the bankruptcy threshold for Cytori, the probability of a change of control event for Cytori, and the risk free interest rate. Fluctuations in the fair value of the Put are impacted by unobservable inputs, most significantly the fair value of Cytori and the Joint Venture and the bankruptcy threshold for Cytori. Generally, a change in the assumption used for the fair value of Cytori and the Joint Venture is accompanied by a directionally opposite change in the fair value of the Put, whereas a change in assumption used for the bankruptcy threshold for Cytori is accompanied by a directionally similar change in the fair value of the Put.

The following assumptions were employed in estimating the value of the Put:

	September 30, 2012			December 31, 2011

Expected volatility of Cytori		78.50	%		76.07	%
Expected volatility of the Joint Venture		78.50	%		76.07	%
Bankruptcy recovery rate for Cytori		28.00	%		28.00	%
Bankruptcy threshold for Cytori	$	21,894,000		$	8,594,000
Probability of a change of control event for Cytori		1.44	%		3.33	%
Expected correlation between fair values of Cytori and the Joint Venture in the future		99.00	%		99.00	%
Risk free interest rate		1.65	%		1.89	%

The Put has no expiration date. Accordingly, we will continue to recognize a liability for the Put and mark it to market each quarter until it is exercised or until the arrangements with Olympus are amended.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements

13. Fair Value Measurements

Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:

· Level 1: Quoted prices in active markets for identical assets or liabilities.

· Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

· Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of			Basis of Fair Value Measurements
	September 30, 2012			Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	13,645,000		$	13,645,000	$	—	$	—

Liabilities:
Put option liability	$	(2,400,000	)	$	—	$	—	$	(2,400,000	)
Warrant liability	$	(1,871,000	)	$	—	$	—	$	(1,871,000	)

	Balance as of			Basis of Fair Value Measurements
	December 31, 2011			Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	30,646,000		$	30,646,000	$	—	$	—

Liabilities:
Put option liability	$	(1,910,000	)	$	—	$	—	$	(1,910,000	)
Warrant liability	$	(627,000	)	$	—	$	—	$	(627,000	)

We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.

We value our put liability using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation) (see note 12). Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the put option liability is classified as Level 3 in the fair value hierarchy.

The following table summarizes the change in our Level 3 put option liability value:

	Nine months ended			Three months ended
Put option liability	September 30, 2012			September 30, 2012

Beginning balance	$	(1,910,000	)	$	(2,100,000	)
Decrease (increase) in fair value recognized in operating expenses		(490,000	)		(300,000	)
Ending balance	$	(2,400,000	)	$	(2,400,000	)

	Nine months ended			Three months ended
Put option liability	September 30, 2011			September 30, 2011

Beginning balance	$	(1,170,000	)	$	(1,280,000	)
Decrease (increase) in fair value recognized in operating expenses		(680,000	)		(570,000	)
Ending balance	$	(1,850,000	)	$	(1,850,000	)

Common stock purchase warrants issued in connection with our August 2008 private equity placement do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the option pricing model. Some of the significant inputs are observable in active markets, such as common stock market price, volatility, and risk free rate. The fair value of these warrants also incorporate our assumptions about future equity issuances and their impact to the down-round protection feature. Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

The following table summarizes the change in our Level 3 warrant liability value:

	Nine months ended			Three months ended
Warrant liability	September 30, 2012			September 30, 2012

Beginning balance	$	(627,000	)	$	(1,008,000	)
Decrease (increase) in fair value recognized in operating expenses		(1,244,000	)		(863,000	)
Ending balance	$	(1,871,000	)	$	(1,871,000	)

	Nine months ended			Three months ended
Warrant liability	September 30, 2011			September 30, 2011

Beginning balance	$	(4,987,000	)	$	(2,809,000	)
Decrease (increase) in fair value recognized in operating expenses		3,714,000			1,536,000
Ending balance	$	(1,273,000	)	$	(1,273,000	)

No other assets or liabilities are measured at fair value on a recurring basis, or have been measured at fair value on a non-recurring basis subsequent to initial recognition, on the accompanying consolidated condensed balance sheet as of September 30, 2012.

- Definition

The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 6
-Footnote 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 33
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Fair Value

9 Months Ended

Sep. 30, 2012

Fair Value [Abstract]

Fair Value

14. Fair Value

Financial Instruments

We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at September 30, 2012 and December 31, 2011, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.

We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.

At September 30, 2012 and December 31, 2011, the aggregate fair value and the carrying value of the Company's fixed rate long-term debt were as follows:

	September 30, 2012				December 31, 2011

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	24,688,000	$	24,858,000	$	24,211,000	$	24,341,000

Carrying value is net of debt discount of $1,142,000 and $1,847,000 as of September 30, 2012 and December 31, 2011, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2012
Stockholders' Equity [Abstract]
Stockholders' Equity	15. Stockholders' Equity Common Stock On December 13, 2010 we raised $10,000,000 in gross proceeds from a sale of 1,428,571 shares of unregistered common stock to Astellas Pharma Inc. for $7.00 per share in a private stock placement. Pursuant to the terms of the purchase agreement, we granted Astellas Pharma Inc. a two year right of first refusal to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions, which will expire on December 14, 2012. In addition, we have agreed to use reasonable efforts to file a registration statement with the Securities and Exchange Commission to register the shares of common stock for resale upon the request of Astellas Pharma Inc. We also granted Astellas Pharma Inc. a non-voting observer seat on our Board of Directors and the right to designate a representative member to our Scientific Advisory Board. The $10,000,000 in total proceeds we received exceeded the market value of our stock at the completion of the purchase agreement. The $2,526,000 difference between the proceeds received and the fair market values of our common stock was recorded as a component of deferred revenues in the accompanying balance sheets. This difference was recorded as deferred revenue since, conceptually, the excess proceeds represent a value paid by Astellas Pharma Inc. attributable to the scientific advisory board seat, the non-voting observer seat on our Board of Directors, and the two year right of first refusal to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions, rather than an additional equity investment in Cytori. The recognition of this deferred amount will occur upon the earlier of the expiration of the two year period or the termination of the agreement. On July 11, 2011, we entered into a common stock purchase agreement with Seaside 88, LP relating to the offering and sale of a total of up to 6,326,262 shares of our common stock. The agreement required us to issue and Seaside to buy 1,326,262 shares of our common stock at an initial closing and 250,000 shares of our common stock once every two weeks, commencing 30 days after the initial closing, for up to an additional 20 closings, subject to the satisfaction of customary closing conditions. At the initial closing, the offering price was $4.52, which equaled to 88% of our common stock's volume-weighted average trading prices, or VWAP, during the ten-day trading period immediately prior to the initial closing date, raising approximately $6,000,000 in gross proceeds. At subsequent closings, the offering price was 90.25% of our common stock's volume-weighted average trading prices during the ten-day trading period immediately prior to each subsequent closing date. We raised approximately $18,233,000 in gross proceeds from the sale of 5,826,262 shares in our scheduled closings through April 9th, 2012. Effective, April 30th, 2012, we terminated the agreement with Seaside 88, LP and we will not sell the remaining and final 500,000 shares that would otherwise have been sold under this agreement. Warrant Adjustments Our March 2009 offering of 4,771,174 shares of our common stock and warrants to purchase up to a total of 6,679,644 additional shares of our common stock with an exercise price of $2.59 per share, our May 2009 equity offering of 1,864,783 shares of our common stock and warrants to purchase up to a total of 3,263,380 additional shares of our common stock with an exercise price of $2.62 per share, our closings with Seaside 88, LP, our October 2010 offering of 4,600,000 shares of our common stock and our December 2010 sale of 1,428,571 shares of our common stock triggered an adjustment to the exercise price and number of shares issuable under the warrants issued to investors in our August 2008 private placement financing. As a result, as of September 30, 2012, the common stock warrants issued on August 11, 2008 are currently exercisable for 2,021,543 shares of our common stock at an exercise price of $5.73 per share. Other Related Party Transactions As of September 30, 2012 and December 31, 2011, Green Hospital Supply, Inc., our distribution partner in Japan and a related party, was a beneficial owner of 5.1% and 5.3%, respectively, of our outstanding shares of common stock. During the three and nine months ended September 30, 2012, we incurred approximately $22,000 and $73,000, respectively, and $54,000 and $116,000 during the three and nine months ended September 30, 2011, respectively, in royalty costs in connection with our sales of our Celution® 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture, respectively. Additionally, in February 2012, we purchased second generation Celution ® Systems and consumable sets from Olympus-Cytori, Inc. joint venture, at a formula-based transfer price aggregating to $1,048,000. As of September 30, 2012 and December 31, 2011, Olympus Corporation was a beneficial owner of 6.8% and 7.1%, respectively, of our outstanding shares of common stock and a beneficial owner of 50% of Olympus-Cytori, Inc. joint venture.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2012
Basis of Presentation [Abstract]
Basis of Presentation	Our accompanying unaudited consolidated condensed financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at September 30, 2012 has been derived from the audited financial statements at December 31, 2011, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2011.

Use of Estimates (Policies)	9 Months Ended
Use of Estimates (Policies)	Sep. 30, 2012
Use of Estimates [Abstract]
Use of Estimates	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, evaluating goodwill for impairment, valuing our put option arrangement with Olympus Corporation, valuing warrants, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories. Actual results could differ from these estimates. Current economic conditions, including illiquid credit markets and volatile equity markets, contribute to the inherent uncertainty of such estimates. Management's estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.

Revenue Recognition (Policies)

9 Months Ended

Sep. 30, 2012

Revenue Recognition [Abstract]

Revenue Recognition

Product Sales

initial consulting services;

license rights and standard operating procedures;

equipment and supplies, installation and training;

database hosting services;

technical support services; and

maintenance services.

Concentration of Significant Customers

Research and Development

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Warrant Liability (Tables)

9 Months Ended

Sep. 30, 2012

Warrant Liability [Abstract]

Schedule of assumptions used to determine fair value of warrants

	As of September 30, 2012			As of December 31, 2011
Expected term	0.87 years			1.61 years
Common stock market price	$	4.41		$	2.20
Risk-free interest rate		0.17	%		0.19	%
Expected volatility		74.94	%		69.98	%
Resulting fair value (per warrant)	$	0.93		$	0.32

Inventories (Tables)

9 Months Ended

Sep. 30, 2012

Inventories [Abstract]

Inventory

Inventories consisted of the following:

	September 30,		December 31,
	2012		2011

Raw materials	$	1,500,000	$	1,503,000
Work in process		328,000		790,000
Finished goods		1,583,000		1,025,000
	$	3,411,000	$	3,318,000

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012

Share-Based Compensation [Abstract]

Performance-Based Restricted Stock Awards

The following table summarizes activity with respect to the performance based restricted stock awards during the nine months ended September 30, 2012:

	Restricted Stock Awards			Weighted Average Grant- Date Fair Value
Outstanding at January 1, 2012		246,225		$	5.82
Granted		276,375		$	3.44
Vested		0
Cancelled/forfeited		(261,300	)	$	5.68
Outstanding at September 30, 2012		261,300		$	3.44
Vested at September 30, 2012		0

Transactions with Olympus Corporation (Tables)

9 Months Ended

Sep. 30, 2012

Transactions with Olympus Corporation [Abstract]

Fair Value Assumptions

The following assumptions were employed in estimating the value of the Put:

	September 30, 2012			December 31, 2011

Expected volatility of Cytori		78.50	%		76.07	%
Expected volatility of the Joint Venture		78.50	%		76.07	%
Bankruptcy recovery rate for Cytori		28.00	%		28.00	%
Bankruptcy threshold for Cytori	$	21,894,000		$	8,594,000
Probability of a change of control event for Cytori		1.44	%		3.33	%
Expected correlation between fair values of Cytori and the Joint Venture in the future		99.00	%		99.00	%
Risk free interest rate		1.65	%		1.89	%

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of			Basis of Fair Value Measurements
	September 30, 2012			Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	13,645,000		$	13,645,000	$	—	$	—

Liabilities:
Put option liability	$	(2,400,000	)	$	—	$	—	$	(2,400,000	)
Warrant liability	$	(1,871,000	)	$	—	$	—	$	(1,871,000	)

	Balance as of			Basis of Fair Value Measurements
	December 31, 2011			Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	30,646,000		$	30,646,000	$	—	$	—

Liabilities:
Put option liability	$	(1,910,000	)	$	—	$	—	$	(1,910,000	)
Warrant liability	$	(627,000	)	$	—	$	—	$	(627,000	)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table summarizes the change in our Level 3 put option liability value:

	Nine months ended			Three months ended
Put option liability	September 30, 2012			September 30, 2012

Beginning balance	$	(1,910,000	)	$	(2,100,000	)
Decrease (increase) in fair value recognized in operating expenses		(490,000	)		(300,000	)
Ending balance	$	(2,400,000	)	$	(2,400,000	)

	Nine months ended			Three months ended
Put option liability	September 30, 2011			September 30, 2011

Beginning balance	$	(1,170,000	)	$	(1,280,000	)
Decrease (increase) in fair value recognized in operating expenses		(680,000	)		(570,000	)
Ending balance	$	(1,850,000	)	$	(1,850,000	)

The following table summarizes the change in our Level 3 warrant liability value:

	Nine months ended			Three months ended
Warrant liability	September 30, 2012			September 30, 2012

Beginning balance	$	(627,000	)	$	(1,008,000	)
Decrease (increase) in fair value recognized in operating expenses		(1,244,000	)		(863,000	)
Ending balance	$	(1,871,000	)	$	(1,871,000	)

	Nine months ended			Three months ended
Warrant liability	September 30, 2011			September 30, 2011

Beginning balance	$	(4,987,000	)	$	(2,809,000	)
Decrease (increase) in fair value recognized in operating expenses		3,714,000			1,536,000
Ending balance	$	(1,273,000	)	$	(1,273,000	)

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Fair Value (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value [Abstract]

Fair value and carrying value of long-term debt

At September 30, 2012 and December 31, 2011, the aggregate fair value and the carrying value of the Company's fixed rate long-term debt were as follows:

	September 30, 2012				December 31, 2011

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	24,688,000	$	24,858,000	$	24,211,000	$	24,341,000

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Capital Availability (Details) - USD ($)	3 Months Ended		9 Months Ended
Capital Availability (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Capital Availability [Abstract]
Net Income (Loss) Attributable to Parent	$ (11,248,000)	$ (8,335,000)	$ (28,455,000)	$ (25,544,000)
Retained Earnings (Accumulated Deficit)	$ (270,904,000)		(270,904,000)		$ (242,449,000)
Net cash provided by (used in) operating activities			$ (23,877,000)	$ (27,424,000)

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Warrant Liability (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
Warrant Liability (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]
Warrant liability, fair value	$ 1,871,000	$ 1,871,000
Changes in fair value of warrants	$ 863,000	$ 1,244,000
Expected term		10 months 13 days	1 year 7 months 10 days
Common stock market price (in dollars per share)	$ 4.41	$ 4.41	$ 2.20
Risk-free interest rate (in hundredths)		0.17%	0.19%
Expected volatility (in hundredths)		74.94%	69.98%
Resulting fair value (per warrant) (in dollars per share)	0.93	0.93	0.32

Long-term Debt (Details)		9 Months Ended
Long-term Debt (Details)	Sep. 09, 2011 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	May 31, 2009 $ / shares	Mar. 31, 2009 $ / shares	Aug. 31, 2008 $ / shares
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share) \| $ / shares				2.62	2.59	8.50
Net proceeds from issuance of Term Loan		$ 0	$ 9,444,000
Fair value of warrants issued in connection with loan	$ 267,000
Effective interest rate (in hundredths)	13.63%
Amended and Restated Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Term Loan remaining balance at date of Amendment		15,600,000
Prorated Fee amount		419,000
Debt Instrument, Unamortized Discount		332,000
Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 25,000,000
Interest Rate (in hundredths)	9.87%
Maturity Date	Mar. 01, 2015
Debt Instrument, Fee description	At maturity of the Term Loan, the Company will make a final payment fee equal to 5% ($1,250,000)
Debt Instrument, Fee Amount	$ 300,000
Warrants issued to lenders (in shares) \| shares	132,891
Date from which Warrants are exercisable	Sep. 09, 2011
Warrant exercise price (in dollars per share) \| $ / shares	3.01
Warrant expiration date	Sep. 09, 2018
Net proceeds from issuance of Term Loan	$ 8,600,000
Debt Instrument, Modification	We accounted for this amendment as debt modification since the terms of the amended Term Loan and the Original Term Loan were not substantially different and as present value of cash flows of the modified instrument (using a net method of comparing the present value of cash flows related to the lowest common principal balance between the old and the new loans) was within 10% of the original debt instrument. Accordingly, the fees associated with the amended Term Loan of $300,000, final payment fee of $1,250,000, and the existing unamortized debt discount from the Original Term Loan of $332,000 will be amortized as an adjustment of interest expense over the term of the Amended Term Loan using the effective interest method.
Term Loan [Member] \| Initial Payments [Member]
Debt Instrument [Line Items]
Number of payments	12
Payment amount	$ 20,833
Term Loan [Member] \| Interim Payments [Member]
Debt Instrument [Line Items]
Number of payments	29
Payment amount	$ 825,000
Term Loan [Member] \| Final Payment [Member]
Debt Instrument [Line Items]
Number of payments	1
Payment amount	$ 825,000
Debt Instrument, Fee Amount		$ 1,250,000

Revenue Recognition (Details) - USD ($)	3 Months Ended		9 Months Ended
Revenue Recognition (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2006
Research and Development Arrangements [Line Items]
Deferred revenues, related party	$ 1,107,000		$ 1,107,000		$ 3,520,000
Research grant and other	2,000	$ 5,000	21,000	$ 19,000
Research and Development Arrangement, total contract value	106,000,000
Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred	$ 4,700,000
Research and Development Arrangement, initial base period	2 years
Olympus and Olympus-Cytori [Member]
Research and Development Arrangements [Line Items]
Deferred revenues, related party						$ 28,311,000
Deferred revenue, related party, revenue recognized	$ 0	0	2,413,000	1,231,000
Cumulative deferred revenue recognized to date	27,204,000		27,204,000
Senko [Member]
Research and Development Arrangements [Line Items]
Research grant and other	$ 0	$ 0	$ 0	$ 0
Revenue Recognized [Member]
Concentration of Significant Customers [Line Items]
Number of customers			1	1
Concentration risk percentage (in hundredths)			16.00%	31.00%
Number of distributors				1
Geographic Concentration Risk [Member]
Concentration of Significant Customers [Line Items]
Concentration risk percentage (in hundredths)			67.00%	68.00%
Credit Concentration Risk [Member]
Concentration of Significant Customers [Line Items]
Number of customers			3	1
Concentration risk percentage (in hundredths)			44.00%	28.00%
Number of distributors				1

Inventories (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Inventories [Abstract]
Raw materials	$ 1,500,000	$ 1,503,000
Work in process	328,000	790,000
Finished goods	1,583,000	1,025,000
Inventory, net	$ 3,411,000	$ 3,318,000

Share-Based Compensation (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
Share-Based Compensation (Details) - USD ($)	Sep. 30, 2012	Mar. 31, 2012	Mar. 31, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Performance Based Restricted Stock Awards [Abstract]
Share-based compensation expense				$ 2,907,000	$ 2,578,000
Stock Options [Member]
Stock Options [Abstract]
Options granted (in shares)		690,000	692,500
Allocated share-based compensation expense		$ 1,373,000	$ 2,375,000
Stock Options [Member] \| Executive officers [Member]
Stock Options [Abstract]
Vesting period		4 years
Options, grant date fair value (in dollars per share)		$ 2.1
Stock Options [Member] \| Directors [Member]
Stock Options [Abstract]
Vesting period		2 years	2 years
Options, grant date fair value (in dollars per share)		$ 1.35	$ 3.15
Stock Options [Member] \| Executive officers and employees [Member]
Stock Options [Abstract]
Vesting period			4 years
Options, grant date fair value (in dollars per share)			$ 3.46
Restricted Stock [Member]
Stock Options [Abstract]
Allocated share-based compensation expense		$ 654,000
Restricted Stock Award [Abstract]
Restricted stock issued during period (in shares)		190,000
Performance-Based Restricted Stock Awards [Member]
Performance Based Restricted Stock Awards [Abstract]
Performance-based restricted stock awards - description of terms				The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company's products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%). To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012. Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards.		The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012. No compensation expense was recognized related to these awards.
Share-based compensation expense	$ 29,000			$ 78,000
Performance-Based Restricted Stock Awards [Roll Forward]
Outstanding (in shares)		246,225		246,225
Granted (in shares)				276,375
Vested (in shares)				0
Cancelled/forfeited (in shares)				(261,300)
Outstanding (in shares)	261,300			261,300		246,225
Vested (in shares)				0
Performance-Based Restricted Stock Awards, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Outstanding - Weighted Average Grant Date Fair Value (in dollars per share)		$ 5.82		$ 5.82
Granted - Weighted Average Grant Date Fair Value (in dollars per share)				3.44
Cancelled/forfeited - Weighted Average Grant Date Fair Value (in dollars per share)				5.68
Outstanding - Weighted Average Grant Date Fair Value (in dollars per share)	$ 3.44			$ 3.44		$ 5.82

Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
Loss per Share (Details) - shares	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Loss per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	18,193,938	19,503,013	18,193,938	19,503,013

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies (Details)	Sep. 30, 2012 USD ($)
Operating leases, Future minimum payments due [Abstract]
Operating leases, Future minimum payments due	$ 9,486,000
Operating leases, Future minimum payments due, next twelve months	1,986,000
Clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase Obligation, Due in Next Twelve Months	3,700,000
Purchase Obligation	11,600,000
Pre Clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase Obligation, Due in Next Twelve Months	23,000
Minimum Purchase Obligation, Supply Agreement [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Minimum purchase obligations, total	2,191,000
Minimum purchase obligations due within one year	$ 1,341,000

Transactions with Olympus Corporation (Details)	1 Months Ended					9 Months Ended	12 Months Ended
Transactions with Olympus Corporation (Details)	Oct. 31, 2010 shares	May 31, 2009 $ / shares shares	Mar. 31, 2009 $ / shares shares	Aug. 31, 2008 USD ($) $ / shares shares	Aug. 31, 2006 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2005 USD ($)
Initial investment by Olympus Corporation in Cytori [Abstract]
Common stock issued (in shares) \| shares	4,600,000	1,864,783	4,771,174
Warrants issued to purchase shares of common stock (in shares) \| shares		3,263,380	6,679,644
Warrant exercise price (in dollars per share) \| $ / shares		2.62	2.59	8.50
Put/Calls and Guarantees [Abstract]
Put Option, Repurchase Floor						$ 22,000,000
Option liability						$ 2,400,000	$ 1,910,000
Fair Value Inputs [Abstract]
Expected volatility (in hundredths)						74.94%	69.98%
Risk free interest rate (in hundredths)						0.17%	0.19%
Cytori [Member]
Fair Value Inputs [Abstract]
Expected volatility (in hundredths)						78.50%	76.07%
Bankruptcy recovery rate for Cytori (in hundredths)						28.00%	28.00%
Bankruptcy threshold for Cytori						$ 21,894,000	$ 8,594,000
Probability of a change of control event for Cytori (in hundredths)						1.44%	3.33%
Expected correlation between fair values and Joint Venture (in hundredths)						99.00%	99.00%
Risk free interest rate (in hundredths)						1.65%	1.89%
Olympus Corporation [Member]
Initial investment by Olympus Corporation in Cytori [Abstract]
Related party transactions				$ 6,000,000	$ 11,000,000			$ 11,000,000
Common stock issued (in shares) \| shares				1,000,000	1,900,000
Sale of stock, price per share (in dollars per share) \| $ / shares				$ 6	$ 5.75
Warrants issued to purchase shares of common stock (in shares) \| shares				500,000
Beneficial Owner, ownership percentage (in hundredths)						6.80%	7.10%
Olympus-Cytori, Inc. Joint Venture [Member]
Formation of the Olympus-Cytori Joint Venture [Abstract]
Joint Venture investment carrying value						$ 122,000
Fair Value Inputs [Abstract]
Expected volatility (in hundredths)						78.50%	76.07%

Fair Value Measurements (Details) - USD ($)	3 Months Ended		9 Months Ended
Fair Value Measurements (Details) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Dec. 31, 2011
Liabilities:
Put option liability	$ (2,400,000)		$ (2,400,000)		$ (2,400,000)	$ (1,910,000)
Change in Level 3 put option liability [Roll Forward]
Beginning balance			(1,910,000)
Ending balance	(2,400,000)		(2,400,000)
Put Option [Member]
Liabilities:
Put option liability	(2,100,000)	$ (1,280,000)	(1,910,000)	$ (1,170,000)	(2,400,000)	(1,910,000)
Change in Level 3 put option liability [Roll Forward]
Beginning balance	(2,100,000)	(1,280,000)	(1,910,000)	(1,170,000)
Decrease (increase) in fair value recognized in operating expenses	(300,000)	(570,000)	(490,000)	(680,000)
Ending balance	(2,400,000)	(1,850,000)	(2,400,000)	(1,850,000)
Change in Level 3 warrant liability [Roll Forward]
Decrease (increase) in fair value recognized in operating expenses	(300,000)	(570,000)	(490,000)	(680,000)
Warrants [Member]
Liabilities:
Warrant liability	(1,008,000)	(2,809,000)	(627,000)	(4,987,000)	(1,871,000)	(627,000)
Change in Level 3 put option liability [Roll Forward]
Decrease (increase) in fair value recognized in operating expenses	(863,000)	1,536,000	(1,244,000)	3,714,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	(1,008,000)	(2,809,000)	(627,000)	(4,987,000)
Decrease (increase) in fair value recognized in operating expenses	(863,000)	1,536,000	(1,244,000)	3,714,000
Ending balance	(1,871,000)	$ (1,273,000)	(1,871,000)	$ (1,273,000)
Fair Value, Measurements, Recurring [Member]
Assets:
Cash equivalents					13,645,000	30,646,000
Liabilities:
Put option liability	(2,400,000)		(2,400,000)		(2,400,000)	(1,910,000)
Warrant liability	(1,871,000)		(1,871,000)		(1,871,000)	(627,000)
Change in Level 3 put option liability [Roll Forward]
Beginning balance			(1,910,000)
Ending balance	(2,400,000)		(2,400,000)
Change in Level 3 warrant liability [Roll Forward]
Beginning balance			(627,000)
Ending balance	(1,871,000)		(1,871,000)
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents					13,645,000	30,646,000
Liabilities:
Put option liability	0		0		0	0
Warrant liability	0		0		0	0
Change in Level 3 put option liability [Roll Forward]
Beginning balance			0
Ending balance	0		0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance			0
Ending balance	0		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Cash equivalents					0	0
Liabilities:
Put option liability	0		0		0	0
Warrant liability	0		0		0	0
Change in Level 3 put option liability [Roll Forward]
Beginning balance			0
Ending balance	0		0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance			0
Ending balance	0		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Cash equivalents					0	0
Liabilities:
Put option liability	(2,400,000)		(2,400,000)		(2,400,000)	(1,910,000)
Warrant liability	(1,871,000)		(1,871,000)		$ (1,871,000)	$ (627,000)
Change in Level 3 put option liability [Roll Forward]
Beginning balance			(1,910,000)
Ending balance	(2,400,000)		(2,400,000)
Change in Level 3 warrant liability [Roll Forward]
Beginning balance			(627,000)
Ending balance	$ (1,871,000)		$ (1,871,000)

Fair Value (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	$ 24,688,000	$ 24,211,000
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	24,858,000	24,341,000
Carrying value of debt discount	$ 1,142,000	$ 1,847,000

Stockholders' Equity (Details)			1 Months Ended					3 Months Ended		9 Months Ended
Stockholders' Equity (Details)	Jul. 11, 2011 USD ($) $ / shares shares	Dec. 13, 2010 USD ($) $ / shares shares	Oct. 31, 2010 shares	May 31, 2009 $ / shares shares	Mar. 31, 2009 $ / shares shares	Aug. 31, 2008 $ / shares shares	Aug. 31, 2006 $ / shares shares	Sep. 30, 2012 USD ($) $ / shares shares	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($) $ / shares shares	Sep. 30, 2011 USD ($)	Dec. 31, 2011 USD ($)
Common Stock [Abstract]
Common stock issued (in shares)			4,600,000	1,864,783	4,771,174
Deferred revenues \| $								$ 5,147,000		$ 5,147,000		$ 5,244,000
Warrant Adjustments [Abstract]
Common stock issued (in shares)			4,600,000	1,864,783	4,771,174
Warrants issued to purchase shares of common stock (in shares)				3,263,380	6,679,644
Warrant exercise price (in dollars per share) \| $ / shares				2.62	2.59	8.50
Astellas Pharma Inc. [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $		$ 10,000,000
Common stock issued (in shares)		1,428,571
Sale of stock, price per share (in dollars per share) \| $ / shares		$ 7
Deferred revenues \| $												$ 2,526,000
Warrant Adjustments [Abstract]
Common stock issued (in shares)		1,428,571
Seaside 88, LP [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $	$ 6,000,000									$ 18,233,000
Common stock issued (in shares)	1,326,262									5,826,262
Sale of stock, price per share (in dollars per share) \| $ / shares	$ 4.52
Common stock purchase agreement, terms	On July 11, 2011, we entered into a common stock purchase agreement with Seaside 88, LP relating to the offering and sale of a total of up to 6,326,262 shares of our common stock. The agreement required us to issue and Seaside to buy 1,326,262 shares of our common stock at an initial closing and 250,000 shares of our common stock once every two weeks, commencing 30 days after the initial closing, for up to an additional 20 closings, subject to the satisfaction of customary closing conditions. At the initial closing, the offering price was $4.52, which equaled to 88% of our common stock's volume-weighted average trading prices, or VWAP, during the ten-day trading period immediately prior to the initial closing date, raising approximately $6,000,000 in gross proceeds. At subsequent closings, the offering price was 90.25% of our common stock's volume-weighted average trading prices during the ten-day trading period immediately prior to each subsequent closing date.
Warrant Adjustments [Abstract]
Common stock issued (in shares)	1,326,262									5,826,262
Green Hospital Supply, Inc [Member]
Other Related Party Transactions [Line Items]
Equity method investment, ownership percentage (in hundredths)								5.10%		5.10%		5.30%
Olympus-Cytori, Inc. Joint Venture [Member]
Other Related Party Transactions [Line Items]
Direct operating cost, royalty expense \| $								$ 22,000	$ 54,000	$ 73,000	$ 116,000
Purchases from related party \| $										$ 1,048,000
Olympus Corporation [Member]
Common Stock [Abstract]
Common stock issued (in shares)						1,000,000	1,900,000
Sale of stock, price per share (in dollars per share) \| $ / shares						$ 6	$ 5.75
Warrant Adjustments [Abstract]
Common stock issued (in shares)						1,000,000	1,900,000
Warrants issued to purchase shares of common stock (in shares)						500,000
Other Related Party Transactions [Line Items]
Equity method investment, ownership percentage (in hundredths)								6.80%		6.80%		7.10%
Variable Interest Entity, Ownership Percentage										50.00%
Warrants issued August 2008 [Member]
Warrant Adjustments [Abstract]
Warrants issued to purchase shares of common stock (in shares)								2,021,543		2,021,543
Warrant exercise price (in dollars per share) \| $ / shares								5.73		5.73